The Filing Desk

Akebia Therapeutics vs IDEAYA Biosciences

Akebia Therapeutics AKBA · IDEAYA Biosciences IDYA · Pharmaceuticals

Akebia Therapeutics reported revenue of $236 million in fiscal 2025, about the same as IDEAYA Biosciences' $219 million in fiscal 2025. Akebia Therapeutics' revenue grew 47.5% in its latest year, and IDEAYA Biosciences' grew 3024.4%. Akebia Therapeutics had an operating margin of 9.9%, against -72.8% at IDEAYA Biosciences. Free cash flow was $68 million at Akebia Therapeutics and −$73 million at IDEAYA Biosciences.

Side by side

Akebia TherapeuticsIDEAYA Biosciences
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$236M$219M
Revenue growth47.5%3,024.4%
Revenue growth a year, last 5 years−4.3%62.2%
Gross margin83.3%—
Operating margin9.9%−72.8%
Net margin−2.3%−52.0%
Free cash flow$68M−$73M
Free cash flow margin28.7%−33.6%
Return on capital——
Net debt to EBITDA−5.5x—
Dividends and buybacks$0M$0M
Change in diluted share count21.9%8.3%
Last close$0.42$26.17
P/E at the last close——
Insider trades, last 12 monthsbought $86,588, sold $962,955bought $1.6 million, sold $382,096
Piotroski F-score7 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Akebia TherapeuticsIDEAYA Biosciences
Operating margin
Percent of revenue
Akebia TherapeuticsIDEAYA Biosciences
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Akebia TherapeuticsIDEAYA Biosciences

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Akebia Therapeutics and IDEAYA Biosciences pages.